Celcuity

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Celcuity 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About CELC

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. 

CEO
Brian F. Sullivan
CEOBrian F. Sullivan
Employees
155
Employees155
Headquarters
Minneapolis, Minnesota
HeadquartersMinneapolis, Minnesota
Founded
2012
Founded2012
Employees
155
Employees155

CELC Key Statistics

Market cap
4.51B
Market cap4.51B
Price-Earnings ratio
-21.40
Price-Earnings ratio-21.40
Dividend yield
—
Dividend yield—
Average volume
811.15K
Average volume811.15K
High today
$93.00
High today$93.00
Low today
$90.72
Low today$90.72
Open price
$91.94
Open price$91.94
Volume
269.04K
Volume269.04K
52 Week high
$151.02
52 Week high$151.02
52 Week low
$44.42
52 Week low$44.42

Stock Snapshot

Celcuity(CELC) stock is priced at $92.21, giving the company a market capitalization of 4.51B. It carries a P/E multiple of -21.40.

On 2026-08-17, Celcuity(CELC) stock traded between a low of $90.72 and a high of $93.00. Shares are currently priced at $92.21, which is +1.6% above the low and -0.8% below the high.

The Celcuity(CELC)'s current trading volume is 269.04K, compared to an average daily volume of 811.15K.

During the past year, Celcuity(CELC) stock moved between $44.42 at its lowest and $151.02 at its peak.

During the past year, Celcuity(CELC) stock moved between $44.42 at its lowest and $151.02 at its peak.

CELC News

TipRanks 5h
Celcuity price target raised to $175 from $165 at Guggenheim

Guggenheim analyst Brad Canino raised the firm’s price target on Celcuity (CELC) to $175 from $165 and keeps a Buy rating on the shares. Celcuity remains well p...

Simply Wall St 2d
The Bull Case For Celcuity Could Change Following Revtopik’s FDA Approval And NCCN Category 1 Status

In August 2026, Celcuity Inc. reported a wider Q2 net loss of US$78.86 million and higher basic loss per share, while securing FDA approval and a preferred Cate...

The Bull Case For Celcuity Could Change Following Revtopik’s FDA Approval And NCCN Category 1 Status
Simply Wall St 4d
Celcuity Wins FDA Approval As Investors Weigh Whether The Pullback Is A Buying Opportunity

Celcuity (CELC) is in focus after receiving FDA approval for REVTORPYK for certain HR+/HER2- metastatic breast cancer patients, along with its inclusion as a pr...

Celcuity Wins FDA Approval As Investors Weigh Whether The Pullback Is A Buying Opportunity

Analyst ratings

100%

of 12 ratings
Buy
100%
Hold
0%
Sell
0%

People also own

Based on the portfolios of people who own CELC. This list is generated using Robinhood data, and it’s not a recommendation.
D-Wave Quantum
Rocket Lab Corporation
IonQ
Micron Technology
Taiwan Semiconductor Manu…
Applied Digital

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.